An official website of the United States government
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Trial Status: active
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed
to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor
activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian
cancer.
Inclusion Criteria
Participants must have a histopathologically confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Key
Exclusion Criteria
Participants with primary platinum-refractory disease. Note: Other protocol-defined inclusion/exclusion criteria may apply.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07226427.
